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# 8 were fixed with paraformaldehyde were labeled with anti-ICAM-1 Mab (A) and 
anti-MHC-1 Mab (B) and TRITC-conjugated goat antimouse secondary Ab. Slide 
A demonstrates high intensity staining for ICAM-1 and slide B demonstrates low 
intensity staining for MHC-1. Cells were examined with X63 oil immersion 
objective on an epifluorescence microscope. 
Figure 2. Immunoperoxidase staining (ABC method) for ICAM-1 in a frozen tissue section 
of canine primary osteosarcoma at low (A) and high (B) magnification. Slides are 
from dog# 2 and demonstrate high staining(+++). 
Figure 3. Immunoperoxidase staining (ABC method) for MHC-1 in a frozen tissue section 
of canine primary osteosarcoma at low (A) and high (B) magnification. Slides are 
from dog# 2 and demonstrate moderate staining(++). 
Figure 4. lmmunoperoxidase staining (ABC method) for ICAM-1 in a formalin-
fixed, paraffin-embedded section of canine primary osteosarcoma at low (A) 
and high (B) magnification showing membrane and cytoplasmic staining. Slides are 
from dog# 6 and demonstrate moderate staining(++). 
Figure 5. Immunoperoxidase staining (ABC method) for MHC-1 in a formalin-
fixed, paraffin-embedded section of canine primary osteosarcoma at low (A) 
and high (B) magnification. Slides are from dog# 7 and demonstrate low staining 
(+). 
Figure 6. Flow cytometry analysis ofB7 surface expression in five canine primary 
appendicular osteosarcoma cell lines. Cells were incubated with recombinant 
hCTLA-4Ig/Fc, biotin-conjugated mouse anti-human IgG and strepavidin cy-
chrome. Human IgG was used as control antibody. All cell lines showed basal B7 
expression. Cells were stimulated with (green) or without (red) 0.5 ng/ml IL-2. The 
blue line represents staining with control human IgG. The ratio for MFI with 
IL-2/MFI without IL-2 is printed in the upper right hand corner for each graph. A 
total number of 10,000 events were analyzed for each sample. 
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ABSTRACT 
Osteosarcoma is the most common primary malignant bone tumor diagnosed in dogs. 
The characteristic aggressive and highly metastatic behavior of this neoplasm indicates that it 
has developed mechanisms to elude the immune surveillance system. The aim of the study 
was to determine whether canine primary appendicular osteosarcomas express ICAM-1, 
:MIIC-1 and B7 surface molecules which are critical in eliciting optimum immune response. 
We have analyzed cell lines and tissue sections (frozen and paraffin-embedded, formalin-
fixed tissues) of dogs diagnosed with osteosarcoma using fluorescence microscopy, flow 
cytometry and immunohistochemistry for the expression ofICAM-1, :MIIC-1 and B7. All of 
the cell lines (n=S) examined by fluorescence microscopy exhibited high ICAM-1 
expression. However, 3 out of 5 cell lines showed moderate expression of :MIIC-1 and we 
observed low expression in two cell lines. We measured B 7 expression using flow cytometry 
on 5 canine primary appendicular osteosarcome cell lines. Analysis of flow cytometry data 
showed that 4 out of 5 canine osteosarcoma cell lines were positive for B7 molecules, with 
the percentage ofB7-expressing cells ranging from 73.67 to 85.13 %. Sections of frozen (n = 
· 7) and paraffin-embedded, formalin-fixed (n = 17) canine appendicular osteosarcoma tissue 
sections were examined by immunohistochemistry for expression ofICAM-1 and WIC-1 
surface molecules. In frozen tumor sections, expression of ICAM-1 was high in tumors 
from 4 out of7 (57.1%) dogs and 3 of7 (43%) dog tumors expressed moderate staining. 
:MIIC-1 expression in tumors was observed in 4 of7 (57.1%) dogs with moderate staining 
while 3 of7 (43%) exhibited low staining. In formalin-fixed, paraffin-embedded tumor 
sections, ICAM-1 showed high staining for tumors from 10 of 17 ( 59%) dogs and moderate 
staining in tumors from 7 of 17 ( 41.2%) dogs. :MIIC-1 showed low expression in tumors 
vu 
from 7 of 17 (41 %) dogs and negative staining in tumors from 10 of 17 (59 %) dogs. The 
results of this study demonstrate a high level ofICAM-1 expression in canine primary 
osteosarcoma, which could possibly explain the invasive nature and rapid metastasis of this 
malignant tumor. While B7 expression suggests, that these tumors are able to deliver 
costimulatory signal but yet manage to escape from immune effector cells perhaps due to low 
WIC-1 expression. These results suggest that the tumor cells could use this strategy to 
interfere with antigen presentation by :MIIC-1 while possibly maintaining inhibitory signal to 
NK cells. 
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CHAPTER 1. LITERA TIJRE REVIEW 
General Introduction 
"Malignant tumors are the ultimate challenge to immunologists, posing profound and 
basic questions concerning tolerance, escape, stimulation, death and survival." (Melief, 
2000) 
Osteosarcoma is the most prevalent primary malignant bone tumor in dogs (Withrow 
et al., 1991). It accounts for 3% to 6 % of all canine cancers and affects 8,000 to 10,000 dogs 
per year in North America (Brodey, 1979). Decreases in osteosarcoma incidence are not 
expected due to the steady popularity of large-to-giant breed dogs as pets. These breeds of 
dogs are the most commonly seen with this tumor. Seventy five percent of the lesions are 
found in the appendicular skeleton (Brodey and Riser, 1969; Misdorp and Haart, 1979). 
Canine osteosarcoma has a highly metastatic behavior to the lungs (Brodey 1979). 
Micrometastasis is present in approximately 90% of dogs at presentation (Brodey and Riser, 
1969). Only 10-15% survive longer than 9 months following diagnosis and amputation {Ling 
et al., 1974; Straw et al., 1990; Vail and MacEwen, 2000). 
Tumor cells are known to escape immune defenses and have developed numerous 
strategies to progress and metastasize. Canine osteosarcoma with its characteristic 
aggressive malignant behavior and high percentage of lung metastasis in the early stages is 
one such tumor that has developed mechanisms to elude the immune surveillance system. A 
long~standing objective in the understanding of the immunobiology and development of 
therapies for tumors is how to achieve an optimum anti-tumor immune response. 
Investigating why canine osteosarcoma continues to escape immune effector mechanisms is 
an important research endeavor. 
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To determine why canine primary appendicular osteosarcoma is able to escape 
immune effector mechanisms, we analyzed the expression of surface molecules involved in 
cell adhesion (ICAM-1 ), antigen presentation and recognition (MHC-1) and costimulation 
(B7) of immune effector cells (Tcells and Natural killer cells). These surface molecules are 
part of the process that leads to tumor destruction and immune memory. In this study, we 
used canine primary appendicular osteosarcoma cell lines and tumor tissues from dogs with 
histologically confirmed primary appendicular osteosarcoma to determine the expression of 
ICAM-1, :MI-IC-I and B7 molecules. Additionally, in conjunction with an ongoing related 
clinical study using osteosarcoma cells transfected with adenoviral vector containing a gene 
for human IL-2 to stimulate antitumor immune response in dogs with primary appendicular 
osteosarcoma, we questioned whether IL-2 altered the expression ofICAM-1, :MI-IC-I and 
B7 molecules of these tumor cells in vitro. 
Canine osteosarcoma 
Incidence 
Osteosarcomas or osteogenic sarcomas are malignant tumors primarily arising in 
bones. They are one of the most common and rapidly growing tumors in dogs (Withrow et 
al., 1991 ). Seventy five percent of osteosarcoma arises in appendicular bones and twenty five 
percent develop in the skull and axial skeleton. Most affected are large breed dogs and giant 
breed dogs (Labrador Retriever, Boxer, Irish Setter, St. Bernard and Great Dane). The 
disease is most likely to occur in middle-aged to older dogs, with a median age of 7 years. 
Males are more frequently at risk than female with a 2: I ratio (Brodey and Riser, 1969; 
Straw et al., 1990). Tumors develop mostly at the metaphyses of the major weight-bearing 
long bones ( distal radius and ulna, proximal humerus and proximal and distal femur, and 
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tibia). Lesions occur almost twice in the forelegs often than the hindlegs (Brodey et al., 1959; 
Brodey et al.1963, Brodey, 1979; MacEwen, 1990). 
Contributing factors to the disease 
The exact cause of osteosarcoma in dogs is unknown. Associated factors include: 
spontaneously occurring, hereditary/genetic determined susceptibility (large breeds 60 times 
at higher risk than small breeds), ionizing radiation, preexisting bone infarcts, metallic bone 
implants and fracture-associated sarcoma (Brodey, 1979). In a case-control study using the 
Veterinary Medical Data Base (V1vIDB) it is reported that the risk of osteosarcoma in dogs 
rose with increasing age, increasing body weight, increasing standard weight and increasing 
standard height. Interestingly, a twofold increase in risk was observed among neutered dogs 
(Ru et al., 1998). Johnson and colleagues (1998) were able to demonstrate point mutations in 
the p53 tumor suppressor gene in 7 of 15 (47%) of dogs with spontaneously occurring 
appendicular osteosarcoma. Another study showed that the MET proto-oncogene, a receptor 
for the cytokine hepatocyte growth factor/scatter factor (HGF) which stimulates the invasive 
growth of neoplastic cells, is abnormally expressed at high levels in canine osteosarcoma 
similar to human osteosarcoma (Ferracini et al., 2000). 
Clinicopathological f ea tu res 
Most dogs at presentation have a history of progressive lameness and usually 
accompanied by a firm, swollen, variably painful mass on the involved long bone (Ling et 
al., 1974). Pathologic fracture is not uncommon due to the destructive nature of the tumor. 
Osteosarcoma is locally destructive and invasive. Metastasis is primarily by invasion of veins 
in the tumor area with embolization of tumor cells to the lungs and to other bones (Brodey et 
al., 1963). Pulmonary metastasis is the major cause of death in dogs with osteosarcoma and 
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tends to occur early in the course of the disease. Studies suggest that micrometastasis is 
present in approximately 90% of dogs at presentation (Straw et al., 1990; MacEwen, 1990; 
Hahn et al., 1994). Grossly, a typical lesion is composed of gritty to hard tumor tissue, which 
involves the entire width of the medullary canal, erodes and penetrates the cortex, and 
extends into the neighboring tissue. The single most important histological characteristic of 
osteosarcoma is the presence of osteoid-forming sarcomatous cells. Sheets of spindle cells 
with interspersed tumor osteoid matrix are normally seen. Many osteosarcomas exhibit 
several variants designated as chondroblastic, fibroblastic, osteoclastic (with numerous giant 
cells), osteoblastic, telangiectatic (have numerous blood-filled cystic spaces), or mixed 
(Brodey, 1963; Ling et al., 1974). 
Cell lines 
Osteosarcoma cell lines provide a useful tool for studying the pathobiology of various 
cancers. Several cell lines have been developed and characterized from spontaneous canine 
osteosarcomas (Kadosawa et al, 1994; Hong et al., 1998; Barroga et al., 1999). These cell 
lines are morphologically a mixed cell type composed of spherical cells, fibroblast -like cells, 
large or small polygonal and multinucleated giant cells. Primary canine appendicular 
osteosarcoma cell lines that can induce transplantable tumors in nude mice were also 
previously described (Nieves et al., 1998). The transplantable tumor's similarity to the 
histologic characteristics of primary canine appendicular osteosarcomas provided a model for 
the future use of these cell lines in various studies about the disease In a related study, cells 
with increased pulmonary metastatic properties, selected from a parent canine osteosarcoma 
cell line, were experimentally grown in nude mice. And thus, could serve as a nude mouse 
model for canine lung metastatic osteosarcoma (Barroga et al., 1999). 
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Model for human disease 
There is a tremendous similarity in the clinical presentation, radiological 
and histopathological features of osteosarcoma in dogs and humans (Brodey, 1979). 
Similarities include: male sex predilection, large patient size, 75% or more affecting the 
appendicular site, metaphyseal location, generally unknown etiology, tumor cells producing 
varying amount of osteoid, and the lung as the most common site of metastasis. Dogs 
therefore have been suggested as a model for the human disease in studying its etiology, 
immunobiology and therapy in humans ( MacEwen, 1990; Withrow et al., 1991; Hahn et al., 
1994). 
Therapy 
Conventional cancer therapies involve surgery, chemotherapy, radiation therapy and 
immunotherapy. A hundred years have past since William Coley observed that tumor 
regression could be induced by activating the immune system with bacterial toxins ( Gore and 
Riches, 1996). The 'immune surveillance theory' of cancer described by Burnet, stated that 
cells of the immune system continuously patrol the body, searching and eliminating cells in 
the process of malignant transformation. This theory further advanced the suggestion of the 
role of the immune system in the growth and spread of tumors (Burnet, 1970). There has 
been a dramatic increase over the years in papers describing the role of the immune system in 
cancer biology. An elegant review by Hanahan and colleagues (2000) summarized 
information on physiologic changes that a normal cell acquires during the process of tumor 
development. These alterations include: self-sufficiency in growth signals, insensitivity to 
growth-Inhibitory (anti-growth) signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis and tissue invasion, and metastasis. 
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Since transformed cells are genetically unstable and acquire multiple mutations, some of the 
proteins that are expressed by these mutated genes could behave as antigens. They concluded 
that in each of these alterations successful evasion of antitumor defense mechanism has to 
occur. With the tightly controlled and multiplicity of immune defenses, a malignant tumor is 
infrequent in an average lifespan of a host. But the enigma is, tumors do exist, they affect 
humans and animals alike and treatment has yet to reach the level of success as in antibiotics 
to treat bacterial infections of vaccines to treat viral diseases. Tumor vaccines are still in the 
beginning stages of development. 
Few immunotherapy approaches have been used in dogs with osteosarcoma. The 
earliest studies recorded the use of freeze-dried bacilli Calmette-Guerin (BCG) (Glaxo strain, 
50-250 x 106 viable organisms) given intravenously to dogs after limb amputation. Seven 
dogs out of20 were alive one-year later (Owen et al., 1977). In dogs receiving macrophage 
activator, liposome-encapsulated muramyl tripeptide-phosphatidyl-ethanolamine(L-MTP-PE) 
disease-free survival time and overall survival was extended, over amputation or no 
treatment when used alone after amputation or after cisplastin chemotherapy (MacEwen, 
1990). Interleukin-2 liposome inhalation therapy in dogs with pulmonary metastasis resulted 
in complete regression of metastasis in two of four dogs treated (Khanna et al., 1997). 
Adjuvant treatment with irradiated clonal human cytotoxic T-cell line TALL- I 04 (proven 
earlier to be effective in treating dogs with malignant histiocytosis), given to dogs with 
osteosarcoma after surgery and chemotherapy resulted in a prevention or significant delay of 
disease recurrence in 9 of 23 dogs (Visonneau et al., 1999). 
Several in vitro experiments showed that canine osteosarcoma cells are sensitive to 
immune effector cells. Canine blood lymphocytes cultured with recombinant IL-2 were 
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shown to have tumoricidal activity towards autologous and allogeneic canine pulmonary 
metastatic osteosarcoma cells in vitro as detected by chromium release cytotoxicity assay 
(Mitchell et al., 1991). Activated canine pulmonary alveolar macrophages exposed in vitro to 
two recombinant canine (re) cytokines, rcTNFa and rcIFNy showed significant cytotoxic 
activity against canine osteosarcoma cells (Kurzman et al., 1999). 
With the assumption that specific tumor associated antigen is present in 
canine osteosarcoma cells that can activate major immune effector cells such as 
cytotoxic T cell (CTL) and natural killer cell (NK), the remainder of this literature review 
focuses on the immunoregulatory surface molecules (i.e., ICAM-1, :MHC-1 and B7) that 
need to be expressed by canine osteosarcoma and are considered critical for optimum 
activation of immune responses. It is theorized that, canine osteosarcoma escapes the 
immune response because it fails to express these immunoregulatory molecules or better yet 
they are expressed aberrantly. CTL provides the antigen-specific, cell-mediated immune 
response while NK provides a non-specific, innate immune response against tumor cells. To 
generate an efficient specific cellular antitumor immune response the following cascade of 
events must occur: (1) antigenic peptides are expressed by the tumor cells, (2) these antigenic 
peptides must bind major histocompatibility complex (MHC) class 1 molecules, (3) 
leukocyte functional antigen- I (LF A-1) on T cells binds ICAM-1 on the target cell, ( 4) the 
first signal, the tumor peptide/MHC class 1 complex recognized by the T cell receptor (TCR) 
on CTL occurs, however, by itself will fail to fully activate effector functions of CTL, (5) 
therefore, the presence of costimulatory signals, as a second signal provided by CD28 on 
CTL binding to B7 on APC and/or tumor cells, then leads to optimum activation, and in this 
case, killing of the tumor cells. NK cells have been shown to be responsible for eliminating 
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growth and metastasis of tumors both in vitro and in vivo (Kiessling et al., 1976; Kim et al., 
2000). The molecular mechanisms behind this lytic activity unfolded with the development 
of the 'missing self hypothesis', which states that NK cells survey cells for normal 
expression ofMHC class I and become activated on contact with cells that have down 
regulated or lost MHC class 1. Target cell specifity of NK cells, is unlike that of CTL with 
their clonally restricted receptor, TCR. NK cells recognize tumor cells through a group of 
inhibitory receptors that recognize MHC class I and stimulatory receptors. ICAM-1 and B7 
molecules are both implicated to provide costimulatory signals to enhance NK cell cytotoxic 
activity. 
Intercellular adhesion molecule-1 (ICAM-1, CD54) 
The intercellular adhesion molecule- I {ICAM-1) is a 90-114 kd surface 
glycoprotein member of the immunoglobulin gene superfamily, with five homologous lg-like 
domains, a single transmembrane region and a short cytoplasmic tail (Rothlein et al., 1986). 
It is expressed constitutively at low levels on a variety of cell types, including those of 
hematopoeitic and nonhematopoeitic origin such as leukocytes, vascular endothelial cells, 
epithelial cells, and fibroblasts. Inflammatory mediators including interleukin- I (IL-1 ), 
tumor necrosis factor (TNF) and _interferon-y {IFN-y) have been shown to upregulate the 
expression ofICAM-1 (Dustin et al., 1986). ICAM-1 serves as a ligand for the P2-l ntegrins, 
LFA-1 (CDI la/CD18) found on almost all leukocytes, including T lymphocytes and Mac-I 
(CDI lb/CD18), which has a more restricted expression on monocytes, macrophages and 
granulocytes (Rothlein et al., 1986; Staunton et al., 1988; Boyd et al., 1988). Since they serve 
as a ligand for LF A-1 and Mac- I, their biological roles have centered on forming homotypic 
and heterotypic adhesions between leukocytes specifically in trafficking of inflammatory 
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cells (Springer, 1990), interaction between antigen-presenting cells and T cells as in the 
formation of immunological synapse (Grakoui et al., 1999) and in providing costimulation 
signals (Chong et al., 1994; Kim et al., 1999; Gaglia et al., 2000; Hubbard and Rothlein, 
2000). Due to this distinctive relationship and its expression on a wide variety of cells, 
ICAM-1 has emerged as a highly important molecule in immune and inflammatory 
responses. 
ICAM-1 is expressed in a wide variety of malignant tumors (Johnson et al., 1989; 
Maurer et al., 1998; Hakansson et al., 1999; Shimoyama et al., 1999; Sun et al., 1999). 
ICAM-1 expression on tumor cells increases their interaction with the immuno-surveillance 
system and provides costimulation to immune effector cells such as T cytotoxic cells and 
NK cells. Mariani and colleagues (1997), demonstrated that human osteosarcoma cell 
lines differ widely in their susceptibility to natural killer cell lysis in vitro. To explain 
this, they investigated the expression of some cell adhesion molecules on osteosarcomas 
to determine which of these can modify their susceptibility to NK lysis. They found that 
cytotoxicity induced by NK cells correlated with differential expression ofICAM-1 on 
osteosarcoma. Use of immunoflourescence confocal laser microscopy showed 
distribution ofICAM-1 on the different osteosarcoma cell lines and correlated the 
expression of ICAM-1 with the capacity of NK cells for binding and lysis of the 
osteosarcoma cells (Meneghetti et al., 1999). 
Since ICAM-1 has been shown to strengthen interactions between immune 
effectors and target cells, the expectation is that its expression on tumor cells would make 
them a better target for cytotoxic cells and should, therefore, be associated with a good 
prognosis. However, contrary to this expectation, ICAM-lexpression in human melanoma 
suggests involvement in the progression of the tumor to metastatic disease. The role of 
ICAM-1 in the development of metastasis was first suggested in human melanoma by 
Johnson and colleagues (1989) after detecting P3.58 antigen that was identical with ICAM-
1 in amino acid sequences. Increased ICAM-1 expression was demonstrated as melanocytes 
transformed to melanomas and continued to increase as they developed to a metastatic state. 
It was speculated that the de novo increased ICAM-1 expression by melanoma cells lead to 
heterotypic adhesion, whereby the tumor cells attach to LF A-1 bearing leukocytes and then 
hitch a ride on the leukocytes as they adhere to vascular endothelium and diapedese, allowing 
spread of the cells from the primary tumor to secondary sites. It has since been used as a 
pr~dictive parameter for the early appearance of metastasis in this tumor type ( see review by 
Johnson, 1991). This manner of metastasis was demonstrated later in other tumors (Simmons 
et al., 1995; Jiang et al., 1998, Sun et al., 1999). However, the precise mechanism by which 
tumor cells migrate through normal vascular endothelium remains controversial. Human 
polymorphonuclear neutrophils (PMNs), which comprise 50-70% of circulating leukocytes, 
were implicated to promote tumor metastasis (Starkey et al., 1984; Welch et al., 1989). 
Recently this hypothesis was tested in vitro by Wu and his group (2001 ), using an in vitro 
transendothelial migration model. This model demonstrated that J\,IDA-:tvm-231, human 
breast adenocarcinoma cells which expressed high levels ofICAM-1, attached and migrated 
with PMN across different endothelial monolayers when treated with tumor-conditioned 
media, (TCM). Interestingly, they also found that incubating the PMNs in tumor-conditioned 
media suppressed PMN cytocidal function as measured by respiratory burst and phagocytosis 
and concomitantly upregulated PMN adhesion receptor expression of CD 11 b/CD 18. Their 
group speculated that the TCM suppressed P:MN cytocidal function and concomitantly 
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upregulated P:MN adhesion receptor (CD 11 b/CD 18) expression. This may indicate that this 
metastatic breast cancer cell line secretes factors capable of altering the phenotype of PMN to 
facilitate transmigration while preventing P?vfN-directed tumor cell damage. The metastatic 
breast cancer cell line might have secreted factors capable of altering the phenotype of PMN 
to facilitate transmigration while preventing P?vfN-directed tumor cell damage. Although it is 
uncertain which of the soluble factors present in TCM is responsible for altered human PMN 
function, tumor cell-produced granulocyte-macrophage colony stimulating factor and IL-3 
have been found, in previous reports, to be responsible for potentiating tumor metastases 
facilitated by tumor-elicited PMN (McGary et al., 1995). 
Manning and collaborators (1995), analyzed the conservation ofICAM-1 amino acid 
sequences in man, chimpanzee, mouse, rat and dog. Their study revealed that canine ICAM-1 
had 61 % identity with human ICAM-1. Cys residues critical to the immunoglobulin fold 
structure and four sites ofN-linked glycosylation are highly conserved from all species. 
Residues critical for human ICAM-1 binding to the f32-lntegrin LFA-1 are highly conserved 
between all species, whereas residues important in binding Mac- I, rhinovirus and malaria-
1 nfected red blood cells are not. This conservation supports the hypothesis that intracellular 
attachment is their primary function. Previous studies of canine ICAM-1 have focused on its 
role in inflammation, and presence on cardiac myocytes, canine endothelial cells (Smith et 
al., 1991), macrophages (Grigg et al., 1994), keratinocytes (Olivry et al., 1995) and 
histiocytoma (Moore et al., 1996). 
Major Histocompatibility Complex class 1 (MHC-1) 
The discovery by Zinkernagel and Shevach (1979) demonstrated that in each 
individual or inbred strain of mouse, T cells are limited to recognizing antigens on the 
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surface of that individual's or strain's cells by virtue of:MHC. This phenomenon is now 
known as :MHC-restriction. The literature has grown immensely in its understanding of the 
role of:MHC class 1 molecules in cell-mediated immunity particularly in anti-tumor 
immunity (reviewed in Tanaka et al., 1988; Khanna et al., 1998; Rees and Mian, 1999). 
Virtually all somatic cells express :MHC class 1 molecules. This class of molecules interacts 
primarily with CTL. They are composed of a large a. (a.1, a.2 and a.3 domains) polymorphic 
transmembrane protein of 45 kDa, non-covalently asssociated with non-polymorphic 12 kDa 
light protein called (32-microglobulin. Peptide presentation to CTL is mediated through a. I 
and a.2 domains forming the peptide-binding groove, which present peptides of a limited 
length (8-10 amino acids), to CDS T+ cells. Sub-site pockets within the grooves of a. I and a.2 
domains specifically interact with side-chains residues from bound peptides. In addition, 
critical to the character of :MHC-1 molecules are that they form stable and rigid complexes 
with peptide antigens. The a.3 domains make noncovalent interactions with the protein (32-
microglobulin to add stability and rigidity to the complex and allow peptide binding to occur 
(Bjorkman, et al., 1987; Bjorkman and Parham, 1990; Rees and Mian, 1999). There are 3 
major human major histocompatibility class I genes, designated as the classical HLA- A, - B, 
or- C and nonclassical - G and - E (Bjorkman and Parham, 1990). 
:MHC class I molecules are expressed by virtually all nucleated cells and are capable 
of binding antigenic peptides that are generated mostly from endogenous proteins (including, 
tumor-associated antigens, T AAs) by the antigen-processing machinery. The peptides are 
presented on the cell surface to TCRs triggering a series of signaling events (cell 
proliferation, cytokine production and target-cell lysis) that can result in tumor cell lysis. 
Several steps are involved in antigen processing and WIC class I cell surface expression. 
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Step one involves degradation of cytoplasmic proteins into short peptides that is mediated by 
the multi catalytic proteasome complex. Step two includes translocation of the peptides into 
the endoplasmic reticulum (ER) by ATP dependent transporters associated with antigen 
processing, T AP-1 and T AP-2. A TAP- Independent pathway, which directly translocates 
peptides into the endoplas~ic reticulum lumen by hydrophobic signal sequences, is another 
possible mechanism of peptide transport to the ER. In step three, peptides may either bind 
directly to freshly synthesized MHC class 1 molecules or may be chaperoned to class 1 
molecules by tapasin. Finally, once the peptide enters the ER lumen, it combines with MHC 
class 1 heavy and f32- microglobulin light chains as a trimolecular complex, traversing 
through the trans-Golgi complex and leading to surface expression (York and Rock, 1996; 
Pamer and Crewell, 1998). Any of these steps can potentially be defective resulting in MHC 
class 1 down-regulation in tumor cells, which may render them resistant to CTL lysis. Many 
human tumors, particularly those of epithelial derivation, appear to express greatly reduced 
levels or completely lack surface class 1 molecules (Garrido et al., 1997). These 
abnormalities can be caused by mutations in the MHC class 1 genes themselves or through 
abnormalities in their regulation and/or defects in MHC class 1 dependent antigen processing 
(Hicklin et al., 1999). Distinct phenotypes arising from these abnormalities have been 
identified. They include: 1) total HLA loss or down-regulation; 2) selective loss or down-
regulation of a HLA class 1 haplotype; 3) selective downregulation of the gene products of 
the HLA-A or HLA-B locus; 4) selective loss or downregulation of a HLA class 1 allele; and 
5) complex phenotypes representing combinations of phenotypes 1-4 (Ferrone and 
Marincola, 1995; Garrido et al., 1997). Combinations of the phenotypes can exist within a 
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given tumor-cell population, generating a heterogeneous pattern ofHLA class 1 expression 
within a tumor lesion. 
NK cells provide the major innate immune defense against tumors and are a backup 
system in case T cells fail to recognize and eliminate tumor cells by virtue of defective MHC 
class 1 expression. The manner of NK killing was previously described as primitive and 
nonspecific in the 1980's (for review see Moretta et al., 2000). The 'missing self hypothesis' 
put forth by Ljunggren and Karre, (1990) along with the discovery of different activating and 
inhibitory receptors of NK cells in the last few years more than illustrate the complexity and 
functional sophistication of these cells. In a nutshell, NK cells survey cells for normal 
expression of MHC class 1 and are activated when there is an abnormality in MHC class 1 
expression. In contrast to TCR on CTL, target cell specifity for the NK cells is through 
interacting signals from activating receptors and inhibitory receptors called killer cell 
inhibitory receptors that recognize MHC class 1, which on ligation inhibits NK cytotoxicity 
and cytokine secretion. NK cells in humans express distinct inhibitory receptors (Colonna et 
al., 2000). Some of which detect shared allelic determinants of class 1 molecules whereas 
others show a broader specifity for different class 1 molecules (Moretta et al., 2000). One 
group of inhibitory receptors belongs to the lg superfamily of type I glycoprotein which 
include killer cell inhibitory receptors (KIR.s) and the human lg-like transcript 2 
(ILT2)/leukocyte inhibitory receptor 1, that specifically recognize groups of class 1 allotypes. 
Another family of inhibitory receptors is a heterodimer of CD94 and NKG2 that recognizes 
HLA-E antigens (Colonna et al., 2000). Thus, expressions ofHLA class I-like molecules, 
such as HLA-E that are nonpolymorphic also provide inhibitory signals to NK cells. When 
transcription/translation of an MHC class 1 molecule is disrupted, or the TAP-dependent 
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tanslocation of their signal sequence peptides into the ER is prevented filA-E expression is 
also inhibited. Since filA-E is a ligand for CD94-NKG2, cells with reduced filA-E 
expression can be eliminated by the NK cell system (Cresswell and Howard, 1999). 
Moreover, NK cells express at least one receptor specific for self-MHC allowing the 
possibility for the whole NK pool of a given individual to detect the loss of even a single 
class I allele on tumor cells (Moretta et al., 2000). If CTL cells and NK cells are working in 
concert to eliminate tumor cells, why then do tumor cells manage to escape cytotoxic 
activities? From the elegant reviews of Garrido (1997) and Ruiz-Cabello (1998), it is 
hypothesized that some tumor cells have devised a stealth strategy of avoiding these two cells 
altogether. B16/FI0.9 melanoma tumor cells express very few MHC class I molecules on the 
cell surface. Nonetheless, class I expression is not completely lost since the tumor cells can 
serve as targets for class I-restricted CTL. It could be that reduction, but not complete loss of 
MHC class I expression to a level that is sufficient for tumor survival as a metastatic lesion, 
is occurring in this particular tumor phenotype (Gilboa et al., 1999). By selectively 
downgrading only certain MHC class I loci, tumors may be resistant to CTL and NK killing 
(i.e., maintaining MHC-1 that specifically interact with killer inhibitory receptors). This 
change would offer a unique survival advantage to tumor cells generating tumor phenotypes 
that can escape these anti-tumor immune effector cells (Rees and Mian et al., 1999). 
Studies on the canine dog leukocyte antigen (DLA) complex demonstrate similarity 
to the human filA ·locus. Development of principles guiding the success in human marrow 
grafting in the last 30 years was initially developed and described in an outbred dog model 
(Storb et al., 1995). There are four DLA class 1 genes namely, DLA-12, -88, -79 and - 61. In 
a polymorphism analysis by Grauman and colleagues (I 998) DLA-88 was found to be 
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significantly more polymorphic than the other three genes. Active research is ongoing to 
determine the tissue distribution of the class 1 genes as well as their function (Wagner et al., 
1999). The constitutive expression of :MHC class 1 in canine mammary tumor and melanoma 
cell lines are reported to range from low to high and expression was increased after canine-
lFN-y treatment (Whitley et al., 1995). 
B7 molecules [B7-1 (CD80) and B7-2 (CD86)] 
B7 molecules are a group of costimulatory molecules belonging to the 
immunoglobulin (lg) supergene family. Initially discovered on activated non-resting B-
lymphocytes, they are given the name "B" (Freeman et al., 1989). There are two major 
family members ofB7: B7-l (CD80) and B7-2 (CD86), which contain extracellular IgV-like 
and IgC2-like domains. B7-l is a 55-kDa glycoprotein made up of288 amino acids with a 
transmembrane region and a short 19 amino acid cytoplasmic domain. B7-2 is a 70-kDa 
glycoprotein made up of329 amino acids, a transmembrane region and a longer cytoplasmic 
domain than B7-l having potential phosphorylation sites for protein kinase C (Freeman GJ, 
1993). Both B7-1 and B7-2 are the natural ligands for CD28 (Linsley et al, 1990) and 
cytotoxic T lymphocyte antigen #4 (CTLA-4) counter-receptors present in T cells (Linsley et 
al, 1991a). Conserved residues found in their V- and C- like domains are critical for their 
binding activity to CD28 and CTLA-4 (Peach et al., 1995). Together with an antigen receptor 
signal (signal 1) interaction ofB7 with CD28 (signal 2) results in T cell activation, clonal 
expansion and development of effector T cell function. In the absence of this second 
costimulatory signal, T cell stimulation will lead to anergy or apoptosis (Linsley et al., 1990; 
Greenfield et al., 1998; Slavik et al., 1999; Sansom, 2000). Numerous studies point to 
inhibition of activation signaling when B7 binds to CTLA-4 (Walunas et al., 1994; Krummel 
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and Allison, 1996). Although both B7-l and B7-2 can provide costimulatory functions and 
bind similarly to CD28 (with low affinity) and CTLA-4 (high affinity), they have several 
distinct differences. They are only approximately 25% identical in their amino acid sequence. 
Another marked difference is that B7-l has a short cytoplasmic tail while the cytoplasmic tail 
ofB7-2 is much longer and contains three potential sites for phosphorylation by protein 
kinase C (PKC) (Freeman et al., 1993). Their manner of expression and distribution also 
differs. B7-l is not detected on resting antigen-presenting cells (APC) such as monocytes and 
B cells and has only minimal expression on dendritic cells (Fleischer et al., 1996). B7-l is 
induced only after activation of the cells. In contrast, B7-2 is constitutively expressed at low 
levels in resting APC and expressed highly in dendritic cells both in situ and during 
maturation in vitro (Caux et al., 1994). B7-2 appears on the surface of the cell more rapidly 
(i.e. within 24 hours ofB cell activation) and abundantly after activation of resting APCs 
whereas B7-l appears more slowly (24-48 hours later) and at lower levels (Hathcock et al., 
1994). Although still controversial (Zheng et al., 1998), many expression studies, together 
with findings in B7-l and B7-2 knockout (KO) mice, indicate that B7-2 is probably the major 
initial ligand for CD28 during T-cell activation, based mainly on its constitutive expression, 
and more rapid and abundant expression on APCs. Thereby, B7-2 may play a pivotal role in 
the decision between T cell activation and anergy. Whereas B7-l, expressed later and more 
slowly, may serve to amplify or regulate an immune response (Lenschow et al., 1996; 
Schweitzer et al., 1997; Manickasingham et al., 1998). 
It still needs to be defined if both B7-l and B7-2 have redundant, overlapping, or 
distinct functions. Moreover, it is somewhat confounding why two ligands share receptors 
that have opposing functions (Martin-Fontecha et al., 1996; Sansom, 2000). Despite these 
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differences in ligand binding and expression kinetics, these molecules appear to support T-
cell activation equally (McAdam, et al., 1998). 
The role ofB7-1 and B7-2 has been studied in tumors. Unlike in APCs where B7 
molecules are abundantly found, studies show that most tumor cells, particularly those of 
nonhematopoeitic origin (Chen et al., 1994) do not naturally express these molecules. 
Attempts were made to remedy the absence or marginal expression ofB7 in tumors. The idea 
is, if tumor cells could be made to express costimulatory molecules, they would become 
better antigen-presenting cells and generate a T lymphocyte response capable of destroying 
the tumor. Expression ofB7-1 and B7-2 was increased in human melanoma cells upon 
culturing the tumor cells with individual cytokines such as IFN-y, GM-CSF, and IL-2, 
(Hersey et al., 1994). Gene transfer was another way to induce their expression in tumor 
cells. Studies of a number of in vitro tumor models such as melanoma, lymphoma, leukemia, 
renal carcinoma, and colon carcinoma, report that tumor cells transfected with B7-1 or B7-2 
used as a vaccine are rapidly rejected and the immune response to them is able to prevent 
challenge with parental cells (Chen et al., 1992; Matulonis et al., 1995; Martin-Fontecha, 
1996; Jung et al., 1999; Takahashi et al., 2000). This did not generalize to all cell types, as 
many sarcoma cell lines tested fail to elicit systemic immunity by B7 transfection (Chen et 
al., 1994). By introducing mouse B7-1 cDNA into a rat osteosarcoma cell line then 
inoculated orthotopically into the tibia of immunocompetent rats (performed to simulate the 
origination of osteosarcoma in the bones). Hayakawa and his group (1997) reported B7-l 
transfectants generated protective as well as curative immunity against B 7-1 negative 
parental osteosarcoma. The soluble form of murine B7-1 was first tested to bind and provide 
costimulatory signals for proliferation of rat T cells before transfection. The differential 
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function ofB7-l and B7-2 in tumors is a subject of continuing study. Interestingly, some 
tumors are found to express B7 molecules although the level -of expression decreases as 
tumors progress and metastasize (Koyama et al., 1998). 
Costimulation by B7-l and B7-2 has also been shown to be necessary for natural 
killer cell activity against tumor cells. Human and murine tumors when transfected with B 7-1 
and B7-2 trigger NK-cell mediated cytoxicity in vitro, although the degree of triggering 
effect differs between individual NK cells clones (Martin-Fontecha et al., 1999; Wilson et al., 
1999; Luque et al., 2000). B7-l and B7-2 are suggested to be candidates for NK cell-
activating ligands on target cells. Controversy still exists, as far as their counter-receptor in 
NK cells. CD28 is expressed on human fetal NK cells but is lost after NK maturation and 
absent on peripheral blood NK cells in adults (Nagler et al., 1989; Sanchez et al., 1993). 
Nevertheless, recent reports that claim detection of CD28 on NK cells could actually depend 
on the monoclonal antibodies used, and indicate the possibility of a variant isotype of CD28 
(Lang SN 1998, Galea-Lauri 1999). These studies show another face ofB7 molecules, 
wherein NK cells, the major nonspecific immune cells involved in eliminating tumor cells, 
appear to have evolved so that they also exploit costimulatory pathways. 
Characterization of B7 molecules in dogs has so far been limited. Yang and 
colleagues (1999), in the process of characterizing dog B7 genes have discovered new, 
naturally occurring forms ofCD80 and CD86 mRNAs that encode soluble forms ofB7-l and 
B7-2 molecules from a dog PBMC cDNA library. To the author's knowledge B7 expression 
on canine tumors particularly in canine osteosarcoma has not been reported. 
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Summary 
In summary, this review presents a description of the clinico-pathological 
characteristics of canine osteosarcoma and previous preventive and multi-modal therapies 
undertaken for this tumor. Its significant similarity with human osteosarcoma and 
characteristic malignancy and rapid metastasis underlies the necessity for continued study of 
this tumor. The critical roles ofICAM-1, :MHC-1 and B7 surface molecules in eliciting 
optimum antitumor response are indispensable. Tumors manipulate the expression of these 
molecules to evade detection and destruction by the immune system. 
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CHAPTER 2. PHENOTYPIC ANALYSIS OF CANINE APPENDICULAR 
OSTEOSARCOMA: EXPRESSION OF ICAM-1, MHC-1 
AND B7 SURFACE MOLECULES 
Introduction 
Osteosarcoma is the most prevalent primary malignant bone tumor in dogs (Withrow 
et al., 1991). It accounts for 3% to 6 % of all canine cancers and affects 8,000 to 10,000 dogs 
per year in North America (Brodey 1979). Decreases are not expected due to the steady 
popularity of large-to-giant breed dogs as pets. These breeds of dogs are the most afflicted by 
this tumor. Seventy five percent of the lesions are found in the appendicular skeleton 
(Brodey and Riser, 1969; Misdorp and Haart, 1979). Canine osteosarcoma has a highly 
metastatic behavior to the lungs (Brodey 1979). Micrometastasis is present in approximately 
90% of dogs at presentation (Brodey and Riser, 1969). Only 10-15% survive longer than 9 
months following diagnosis and amputation (Ling et al., 1974; Straw et al., 1990; Vail and 
MacEwen, 2000). 
Canine osteosarcoma has developed mechanisms to elude the immune surveillance 
system with its characteristic aggressive malignant behavior and high percentage of lung 
metastasis in the early stages of this neoplasm. To understand why canine osteosarcoma 
continues to escape immune effector mechanisms, it will be necessary to analyze the 
expression of surface molecules such as ICAM-1, MHC-1 and B7 that are critical to eliciting 
optimum i~mune response against these tumor cells. 
Several reasons may account for escape of tumor cells from immune recognition. One 
mechanism to avoid an immune response is that tumors may alter MHC-1 expression. 
Antigens must be presented in the context of MHC-1 molecules to be recognized by T 
lymphocytes. Abnormal expression of MHC-1 makes them susceptible to natural killer cell 
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killing. Some tumors can selectively downgrade certain 1\1HC loci ( as much as 70% 
reduction for example in human cervical carcinoma with a loss ofHLA-B44) and thereby 
develop resistance to cytotoxic T cells (via loss of certain 1\1HC-l molecules) and NK killing 
by maintaining MHC that specifically interact with killer-cell inhibitory receptors (Garrido et 
al., 1997). 
A second mechanism could be the absence of costimulation, which renders T cells 
unresponsive, or anergic. B7 molecules present on antigen-presenting cells interact with 
CD28 receptor on T cells to provide a costimulatory signal for optimum T cell activation. 
Even though some tumor cells display MHC class I tumor-associated antigen on their 
surface, they usually .do not an elicit immune response and this unresponsiveness is perhaps 
due to the lack ofB7. Unlike antigen-presenting cells on which B7 molecules are abundantly 
found, studies show that most tumor cells, particularly those of nonhematopoeitic origin 
(Chen et al., 1994) do not naturally express these molecules and this may prevent the 
induction of efficient antitumor immune responses. 
A third potential mechanism for tumors to avoid immune surveillance involves 
expression ofICAM-1. The interactions between ICAM-1 and its ligand, leukocyte 
functional antigen- I (LF A-1) plays a fundamental role in the course of inflammatory and 
immune responses. Primarily an adhesion molecule, ICAM-1 provides stable conjugates 
between cells through its ligand, LF A-1 (Springer, 1990). By expressing ICAM-1, tumor 
cells are capable of binding to CTL and NK cells with the possibility of killing the tumor or 
cell. ICAM-1 is not expressed by a majority of malignant tumors; however its presence has 
been correlated with tumor progression and metastasis (Johnson, 199 I). Several studies show 
that in some tumors, ICAM-1 expression is not detrimental to their growth but instead is used 
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for metastasis (see review by Johnson, 1991; Simmons, 1995; Jiang et al., 1998; Sun et al., 
1999). 
In this study, we have used primary canine appendicular osteosarcoma cell lines and 
tumor tissues :from dogs with histologically confirmed primary appendicular osteosarcoma to 
determine the expression ofICAM-1, :MHC-1 and B7 molecules. Additionally, in 
conjunction with an ongoing related clinical study using canine osteosarcoma cells 
transduced with an adenoviral vector containing a gene for human IL-2 to direct secretion of 
IL-2 by the tumor cells and stimulate antitumor immune response in dogs with primary 
appendicular osteosarcoma, we examined ifIL-2 alters the expression ofICAM-1, :MIIC-1 
and B7 molecules on these tumor cells in vitro. 
Materials and Methods 
Preparation of Samples 
Tumor specimens were aseptically obtained :from surgical biopsy of dogs clinically 
diagnosed with primary appendicular osteosarcoma at the Iowa State University Teaching 
Hospital and processed for cell culture and immunohistochemistry. For 
immunohistochemistry, a section of the tumor tissue was formalin-fixed and paraffin-
embedded, and another section wa,s embedded in optimum cutting temperature (O.C.T.) 
compound (LAB-TEK products, Division Miles Lab, Inc. Naperville, IL), snap :frozen in 
liquid nitrogen, and stored at -70 °C. All cases were immunohistopathologically diagnosed as 
osteosarcoma. Testing for serum alkaline phosphatase was performed at the time of surgery 
by the Iowa State University Clinical laboratory. 
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Generation of primary cell lines 
The generation of primary tumor cell lines was performed as previously described 
(Nieves, et al., 1998). Briefly, tumor samples were aseptically obtained from surgical biopsy 
of dogs clinically diagnosed with primary appendicular osteosarcoma at the Iowa State 
University Teaching·Hospital, College of Veterinary Medicine, Iowa State University. The 
tissues were placed in a sterile 50 ml centrifuge tube with 30 ml of digestion media 
containing Hank's balanced salt solution (Gibco BRL Grand Island, NY), 5µg/ml of 
Hyaluronidase (3,600 U/mg, Sigma Inc. St. Louis, MO), 30mg/ml ofCollagenase type IV 
(Sigma) and 1 mg/ml ofDeoxyribonuclease (Sigma) and incubated in a 37°C water bath and 
gently agitated every 5 minutes. After 30 minutes, the supernatant together with the cells 
sieved through a sterile wire mesh (size 50). The disaggregated tumor tissues were collected 
and centrifuged at 1,500 rpm for 10 minutes. The pellet was washed and resuspended in 
Dulbecco's modified essential medium, 10% fetal bovine serum and antibiotics (100 U/ml 
Penicillin and 100 g/ml Streptomycin). Cells were seeded in a 25 cm2 tissue culture flask and 
incubated at 37°C in a humidified 5% CO2, 95% air incubator. The following day, the culture 
medium was replaced to remove non-adherent cells and thereafter media was changed every 
other day. After reaching 80-90 % confluency, cells were detached by using trypsin/EDT A 
and subcultured into fresh culture media. Cells were preserved at 10 7 cells/ml cryotubes with 
DMEM medium containing 30% fetal bovine serum and 10% dimethylsulfoxide. After 48 
hours at -70°C, frozen cultures were transferred to a liquid nitrogen freezer. Not more than 
10 culture passage levels were used to minimize occurrences of intra-tumor variability. 
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Monoclonal antibodies and recombinant protein antibodies 
The group of Smith ( 1991) developed two monoclonal antibodies against canine 
ICAM-1, CL18/D8 and CL18/6. CL18/1D8 was used for most of the studies because it 
demonstrated less background staining than CL 18/6, although similar patterns of staining 
were seen in both monoclonal antibodies (Grigg et al., 1994; Olivry et al., 1995; Moore et 
al., 1996). The mAb H58A, which specifically binds to H-2k1' equivalent MHC class 1 
molecules on cells from several animals including dog was used to evaluate the expression of 
:MHC class 1, (Whitley et al., 1995). Since monoclonal antibodies against canine B7-l and 
B7-2 are not yet available at the·time of this study, we used hCTLA-4Ig/Fc chimera (R & D 
Systems, Inc. Minneapolis, MN) to detect the expression ofB7 on canine osteosarcoma cells 
(Pinelli et al., 1999). CTLA4-lg is a fusion protein generated by a construct in which the 
external domains of CTLA-4 have been fused to the Ig-C domains of human Igy (Linsley, 
1991). 
Immunofluorescence and fluorescence microscopic analysis of ICAM-1 and MHC-1 
Cells were grown on sterile coverslips and incubated overnight at 3 7°C in a 
humidified 5% CO2, 95% air incubator. To detect ICAM-1 expression, cells were fixed with 
4% paraformaldehyde (Polysciences, Inc., Warrrington, PA) in phosphate buffered solution 
for IO minutes. After 10 minutes, the fixative was replaced with fresh fixative and incubated 
for another 30 minutes. To detect MHC-1, cells were fixed with ice-cold ethanol. After 
fixation, cells were washed with PBS three times and incubated with blocking buffer (5% 
normal goat serum, 4.5% bovine serum albumin (BSA) and 0.1% Triton X-100 in PBS). 
After the blocking solution was removed, cells were incubated with I : 100 dilution of primary 
specific monoclonal antibodies against ICAM-1 (CL18/ID8) and w-IC-1 (H58A) overnight 
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in a humidified chamber at 4°C. Cells were washed three times with wash buffer (5% 
normal goat serum, 0.5% BSA and 0.1% Triton X-100 in PBS). For immunofluorescence 
detection, the cells were incubated with goat anti-mouse lgG (H+L} TRITC (Sigma 
Chemicals, St. Louis, MO) that was diluted I :200 with wash buffer for 3-4 hours in the dark 
at room temperature. After two additional washes in PBS and three washes in distilled water, 
coverslips were mounted on glass slides with n-propyl gallate glycerol. Fluorescence was 
visualized on epifluorescence microscope. Controls included samples run in parallel that 
were incubated without primary antibodies, samples incubated with only primary antibodies 
and samples incubated with an immunoglobulin isotype control. Due to homogenous nature 
of the population of tumor cells, results were interpreted according to staining intensity of the 
cells (Table la). 
Immunohistochemical analysis ofICAM-1 and MHC-1 
Frozen Tissue Sections 
Frozen tissue sections were immunostained according to standard avidin-biotin-
peroxidase complex (ABC) procedure (Hsu et al., 1981 ). Briefly, frozen tissue sections were 
cut at 4µ, air-dried and fixed in acetone at 4°C, and washed for 5 minutes with PBS. Tissue 
sections were encircled with a water-repellent barrier PAP pen (BioGenex, San Ramon, CA) 
before proceeding to the rest of the immunostaining procedure. Endogenous peroxidase 
activity was quenched with 0.3% hydrogen peroxide, and washed in PBS. Tissues were 
overlaid with a protein-blocking solution containing 2% BSA and 10% normal horse serum 
(Vector Laboratories, Burlingame, CA) at room temperature to block non-specific staining 
(nonimmune binding of immunoglobulins to the tissue). After incubation, the solution was 
tapped off without rinsing. Tissue sections were incubated with primary mouse monoclonal 
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Table la. Scoring of immunostained cell lines. 
Staining Intensity 
Negative 
Low 
Moderate 
High 
Score 
(-) 
(+) 
(++) 
(+++) 
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antibodies against ICAM-1 and MHC-1 overnight in a humidified chamber at 4°C. The 
working dilution for both monoclonal antibodies was I : 100. All subsequent procedures were 
carried out at room temperature. After washing with PBS, sections were incubated with 
biotinylated horse antimouse secondary antibody (Vectastain Elite ABC kit, Vector 
Laboratories, Burlingame, CA) diluted 1 :200. Following three washes with PBS, avidin-
biotin peroxidase complex, (ABC) solution (Vectastain ABC kit, Vector Laboratories, 
Burlingame, CA) prepared according to the manufacturer's direction was applied to the 
tissues. Slides were then washed with PBS and incubated with NOV Ared (Vector 
Laboratories). Following a rinse in ultra pure water, tissues were counterstained with 
haematoxylin (Vector Laboratories), rinsed with water, dehydrated through increasing 
concentrations of ethanol, cleared in xylene and mounted with Acrytol (Surgipath Lab, 
Richmond, IL). 
Paraffin-embedded Tissue Sections 
Formalin-fixed, paraffin-embedded, tissues were sectioned at five-micron and 
mounted on poly L-lysine coated microscope slides. Before immunostaining, slides were 
heated for 30 minutes at 60 °C. Sections were deparaffinized in 2 changes of xylene and 
rehydrated by passage through 100%, 95% and 70% ethanol and rinsed with ultrapure water. 
For antigen retrieval, the slides for staining ICAM-1 were placed in a plastic staining dish 
with 250 ml of sodium citrate buffer (IOmM,pH 6.0) while on slides for staining MHC-1, the 
antigen retrieval Glyca, (pH 4.0, BioGenex, San Ramon, CA) was used. The slides were 
then heated in a microwave at high power until the solution was boiling (2. 5 minutes). Slides 
were heated another 10 minutes on low power. The slides were allowed to cool in the freezer 
and rinsed once with PBS. Tissue sections were encircled with a water-repellent barrier PAP 
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pen (BioGenex, San Ramon, CA) before proceeding to staining steps. Endogenous peroxide 
activity was quenched by incubating the tissues with 3% hydrogen peroxide at room 
temperature, followed by washing in PBS. The rest of the immunostaining procedure was 
performed as described above in frozen tissue sections using antibodies to ICAM-1 and 
:tvrn:C-1. 
To expand the number. of formalin-fixed, paraffin-embedded tissue sections 
examined, an additional 4 histopathological cases of dogs with osteosarcoma were included 
for the investigation ofICAM-1 and MFIC-1 expressions. Controls included serial sections 
mn in parallel that were incubated in the absence of the primary antibodies and sections 
incubated with an isotypic lgG control antibody at the same concentration as the primary 
mAb used in the analysis. Results were classified according to percentage of tumor cells that 
were stained positive (i.e., extent of staining) (Table lb). 
Immunofluorescence and flow cytometry analysis of B7 
Osteosarcoma cells were detached from tissue culture flasks by incubation with 5 ml 
1 % Na2 ethylenediamine tetraacetic acid (EDT A) in PBS for 10 minutes at room temperature 
and washed twice in ice-cold wash buffer solution (0.5% BSA, 0.025% Na azide and 25mM 
HEPES in PBS)·at 4° C. Aliquots of 105 cells were stained with 6 µg of CTLA-4 lg/Fe 
chimera (R & D Systems, Inc. Minneapolis, MN) diluted in wash buffer in an ice water bath. 
After incubation, cells were washed with ice-cold wash buffer. Biotin conjugated mouse anti-
human IgG secondary antibodies, 6 µg (Sigma) were added to the cells. Cells were washed 
then incubated a third time with 50 ng of Strepavidin Cy-Chrome (PharMingen, San Diego, 
CA). After one washing, cells were fixed with 1 % paraformaldehyde in PBS for flow 
cytometric analysis. Analysis was carried out with EPICS XL-MCL flow cytometer 
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Table I b. Scoring of immunostained tissue sections. 
Percent of Tumor Cells Stained 
< 10 
10 to 25 
25 to 50 
> 50 
Score 
(-) Negative 
(+) Low 
( ++) Moderate 
(+++) High 
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(Beckman-Coulter). Control staining was performed with isotype-matched human lgG 
(Sigma) and with the biotin-conjugated reagent only. All incubations were performed at 4°C 
in an ice water bath. 
IL-2 stimulation of canine osteosarcoma cells 
Two cell lines were grown on coverslips and were stimulated with or without rIL-2 
(Sigma) at 0.5ng/ml for 24 hour at 37°C in a humidified 5% CO2, 95% air incubator. 
Following staining against ICAM-1 and MHC-1, cells were examined and images stored by 
using X63 oil immersion objective on a Leica TCS-NT confocal laser microscope. To 
examine the effect ofIL-2 on B7 expression, one cell line was first incubated with different 
concentrations of rIL-2 (0.50ng/ml, 1.25 ng/ml and 2.50 ng/ml) for 24 hours at 37°C in a 
humidified 5% CO2, 95% air incubator, stained with hCTLA4-lg and analyzed by flow 
cytometry as described above. After staining, 0.50 ng/ml of rIL-2 was chosen as the optimum 
dose that affected B7 expression on canine osteosarcoma cell lines, four cell lines were 
additionally stimulated with or without rIL-2 at 0.5ng/ml for 24 hour at 37°C in a humidified 
5% CO2, 95% air incubator. Cells were stained with hCTLA-4Ig/Fc and analyzed with flow 
cytometry as described earlier. 
Statistical analysis 
A Student's !-test was used to evaluate the statistical difference (P<0.01) of the mean 
fluorescence intensity of paired samples. 
Results 
Patient characteristics 
The dogs were diagnosed with osteosarcoma based on standard radiographs and 
histologic evaluation of biopsy samples following tumor excision. Table 2 summarizes the 
Table 2. Summary of clinicopathological data of canine primary appendicular 
osteosarcoma cases. 
DFI6 Age Histological sAP ST 
Dog Breed Sex Years Location Classification IU/La mos mos Metsb Comments 
1 Rottweiler M 7.0 Humerus osteosarcoma 217 2 8 + w/ lung mets after 2 mos 
2 Irish wolfhound F 2.6 Distal Humerus osteosarcoma 51 2.5 1.3 + w/ lung/heart mets after 2.5 mos 
3 Dobennan F 6.8 Femur osteosarcoma 336 NRb leg amputation, ok as of last entry 
Pinscher 
4 Labrador M 2.0 Proximal Humerus chondroblastic 42 1 + w/ lung mets after 1 mo 
Retriever osteosarcoma 
5 Rottweiler F 8.6 Midshaft Femur osteoblastic 101 1 + w/ mets after 1 mo, local invasion 
osteosarcoma 
6 Greyhound F 7.8 Distal Radius osteosarcoma 26 0.1 NR bone biopsy only 
7 Mixed F 4.5 Tibia Fibula fibroblastic 76 - no mets, ok as of last entry 
osteosarcoma 
8 Labrador F 6.0 Distal Radius osteosarcoma 97 11 - no mets, tumor unrelated death 
Retriever 
9 Dalmatian F 5.4 Proximal osteosarcoma 53 NR bone biopsy only 
Humerus 
10 Mixed F 8.0 Tibia osteosarcoma 0 NR bone biopsy only °' 
11 Rottweiler M 5.3 Distal Radius 118 NR bone biopsy only 
12 German F 3.6 Femur osteosarcoma 0 NR bone biopsy only 
Wirehair Pointer 
13 Great Pyrenes F 7.0 Distal Tibia pareostal 99 + w/ lymph node mets 
osteosarcoma 
14 Boxer F 2.0 Proximal osteoblastic 0 1 + w/ lung mets after 1 mo 
Humerus osteosarcoma 
15 Rottweiler M 4.3 Distal Tibia osteosarcoma 90 NR 
16 Rottweiler F 1.0 Distal Ulna osteosarcoma 8 NR 
17 Rottweiler F 9.0 Distal Femur osteosarcoma 245 NR 
a serum Alkaline phosphatase normal range is O - 100 IU/L 
'DFI - disease-free interval time, ST - survival time, mets - metastasis, NR- not recorded 
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clinical features of dogs entered for the study. The dogs ranged in age from 1 year to 9 years 
with an average age of 5.4 years. There were 13 females and 4 males. Fifteen of 17 dogs 
were from purebred large to giant breeds, while 2 of 17 dogs were mixed breed. The 
Rottweiler was the predominant breed (6 out of 17 dogs) in this study. Tumor was found in 
one of four major weight-bearing bones (humerus, radius, ·femur and tibia) in all the cases. 
Foreleg lesions were found in 9 cases and hindleg lesions in 8 cases. 
Table 2 also shows that 12 of 17dogs (71%) had serum alkaline phosphatase (sAP) 
levels within the normal range of O to 100 IU/L, while only 5 dogs (29%) had sAP levels 
exceeding the normal range. Of the Rotweiller dogs, 4 of 6 ( 67%) showed a sAP level 
exceeding the normal range. 
Where data was available, 6 dogs showed metastasis and 2 dogs had no metastasis. 
Among the 6 dogs with metastasis, two had sAP levels above the normal range, and the other 
4 dogs had sAP levels within the normal range. The 2 dogs with no metastasis had sAP levels 
within the normal range. 
Dog 1 with lung metastasis after 2.5 months from initial diagnosis had a survival time 
(ST) of 8 months. While Dog 2 with lung and heart metastasis after 2.5 months from initial 
diagnosis had a survival time of 1.3 months. Dogs 4 and 14 after initial diagnosis showed 
lung and lymph nodes metastasis, respectively, and had a disease-free interval time (DFI) of 
one month. One dog (8) had a survival time of 11 months but died of tumor unrelated death. 
Data are not complete on DFI and ST because some dogs were lost during the follow up. 
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Detection of ICAM-1 and MHC-1 expression in canine primary appendicular 
osteosarcoma cell lines 
All five cell lines examined expressed high level ofICAM-1. Diffuse membrane and 
cytoplasmic staining distribution ofICAM-1 was observed in the cells (see Figure la). Three 
of the cell lines showed moderate expression ofMHC-1 while weak expression (see Figure 
lb) was observed in two cell lines (Table 3). Punctate to speckled MHC-1 staining on the 
membrane surface of the cells is shown in Figure lb. 
Detection ofICAM-1 and MHC-1 expression in tissue sections of canine osteosarcoma 
Frozen tissue sections 
For frozen tumor sections (Table 4 and Figure 2) a high percentage of staining was observed 
for ICAM-1 in tumors from 4 of 7 ( 57 .1 % ) dogs and 3 of 7 ( 43%) tumors expressed 
moderate staining. MHC-1 expression was observed in 4 of7 (57%) tumors with moderate 
staining while 3 of7 (43%) tumors expressed staining (Figure 3). Almost the same pattern of 
staining was seen in ICAM-1 for formalin-fixed, paraffin-embedded tumor sections (Table 5 
and Figure 4). ICAM-1 showed high staining expression in tumors from 10 of 17 dogs 
(59%) and moderate staining expression in tumors from 7 of 17 (41.2%) dogs. MHC-1 
showed low expression in tumors from 7 of 17 (29 % ) dogs and negative staining in tumors 
from 10 of 17 (59 %) dogs (Figure 5). There were more cells positive for MHC-1 staining 
observed in frozen tissue sections than in paraffin tissues. 
Detection of B7 expression in canine primary appendicular osteosarcoma cell lines 
Flow cytometric analysis of the expression ofB7 in canine osteosarcoma cell 
lines shows that 4 of 5 cell lines demonstrated a high proportion of positive staining ranging 
from 73.67 to 85.13% (Table 6 and Figure 6). 
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Figure 1. Indirect immunofluorescence of canine primary osteosarcoma cells. Cells from dog 
# 8 were fixed with paraformaldehyde were labeled with anti-ICAM-1 Mab (A) and 
anti-MHC-1 Mab (B) and TRITC-conjugated goat antimouse secondary Ab. Slide 
A demonstrates high intensity staining for ICAM-1 and slide B demonstrates low 
intensity staining for MHC-1. Cells were examined with X63 oil immersion 
objective on an epifluorescence microscope. 
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Table 3. Expression ofICAM-1 and :MIIC-1 in canine primary appendicular 
osteosarcoma cell lines. 
Cell lines ICAM-1 :MIIC-1 
1 +++ ++ 
2 +++ ++ 
8 +++ + 
9 +++ + 
14 +++ ++ 
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Table 4. Immunohistochemical analysis ofICAM-1 and :MHC class I expression in frozen 
canine primary appendicular osteosarcoma tissues. 
Dog ICAM-1 :MHC-1 
2 +++ ++ 
3 ++ ++ 
4 +++ + 
5 +++ + 
6 ++ + 
7 +++ ++ 
18 ++ ++ 
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Figure 2. Immunoperoxidase staining (ABC method) for ICAM-1 in a frozen tissue section 
of canine primary osteosarcoma at low (A) and high (B) magnification. Slides are 
from dog# 2 and demonstrate high staining(+++). 
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Figure 3. Immunoperoxidase staining (ABC method) for MHC-1 in a frozen tissue section 
of canine primary osteosarcoma at low (A) and high (B) magnification. Slides are 
from dog# 2 and demonstrate moderate staining(++). 
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Table 5. Immunohistochemical analysis ofICAM-1 and MHC class 1 expression in formalin-
fixed, paraffin-embedded canine primary appendicular osteosarcoma tissues. 
Dogs 
19 
2 
3 
5 
6 
7 
9 
10 
11 
12 
13 
15 
16 
17 
20 
21 
22 
ICAM-1 
+++ 
+++ 
+++ 
+++ 
++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
+++ 
+++ 
+++ 
++ 
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Figure 4. Immunoperoxidase staining (ABC method) for ICAM-1 in a formalin-
fixed, paraffin-embedded section of canine primary osteosarcoma at low (A) 
and high (B) magnification showing membrane and cytoplasmic staining. Slides are 
from dog# 6 and demonstrate moderate staining(++). 
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Figure 5. Immunoperoxidase staining (ABC method) for MHC-1 in a formalin-
fixed, paraffin-embedded section of canine primary osteosarcoma at low (A) 
and high (B) magnification. Slides are from dog# 7 and demonstrate low staining 
(+). 
57 
Table 6. Mean fluorescent intensity (MFI) ofB7 with or without IL-2 stimulation of 
canine primary appendicular osteosarcoma cells. 
% Positive :MFI 
IL-2 Ratio 
Cell lines B7a Baseline Stimulation Stimulation/Baseline 
1 6.58 2.22 3.82 1.72 
2 77.03 8.97 11.80 1.32 
3 85.13 13.5 22.20 1.64 
4 73.67 9.30 16.10 1.73 
5 78.50 4.34 4.80 1.11 
a Each value represents the percentage of positive hCTLA4lg stained cells minus the 
percentage of cells stained by isotype control. The expression of B7 was determined by 
indirect immunoflourescence and FACS analysis by using hCTLA4Ig/Fc. 
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Figure 6. Flow cytometry analysis ofB7 surface expression in five canine primary 
appendicular osteosarcoma cell lines. Cells were incubated with 
recombinant hCTLA-4Ig/Fc, biotin-conjugated mouse anti-human IgG and 
strepavidin cy-chrome. Human IgG was used as control antibody. All cell lines 
showed basal B7 expression. Cells were stimulated with (green) or without (red) 0.5 
ng/ml IL-2. The blue line represents staining with control human IgG. The ratio for 
1\,1FI with IL-2/W'I without IL-2 is printed in the upper right hand comer for each 
graph. A total number of 10,000 events were analyzed for each sample. 
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Regulation of ICAM-1, MHC-1 and B7 expression in canine primary appendicular 
osteosarcoma by IL-2 
IL-2 is a potent stimulator of cytotoxic T cells, NK, LAK and helper T cells. We were 
interested in knowing if the presence ofIL-2 would alter canine osteosarcoma expression of 
ICAM-1, MHC-1 and B7 surface molecules. The two cell lines examined showed diffuse 
membrane and cytoplasmic distribution ofICAM-1 with a high level of expression. The 
staining intensity and distribution detected on the two cell lines after IL-2 treatment showed 
diffuse membrane and cytoplasmic distribution of ICAM-1 with a high level of expression. 
Thus, no apparent change was detected in cells that were IL-2 stimulated as compared with 
cells not stimulated by IL-2. 
The two cell lines stained for Wf C-1 showed moderate expression with punctate to 
speckled staining on the membrane surface of the cells. There was no change of staining 
intensity or staining distribution of WIC-1 detected in cells that were stimulated with IL-2 
from the cells not stimulated with IL-2. 
The regulatory effect ofIL-2 on the surface expression ofB7 was determined in five . 
cell lines. Data is expressed as mean fluorescence intensity value (W'I), an indirect 
expression of antigen density. Slight shifts in the histograms were observed (Figure 5). 
However, with the large number of cells from each sample dog (N=I0,000), it is expected 
that any noticeable difference in the location of the two histograms is likely to be statistically 
significant (Shapiro, 1988). The Student's I-statistics demonstrates that the paired 
differences in the histograms were statistically significant (P<0.01). However, ratios ofMFI 
stimulated/MF! baseline less than 2 are considered small. The stimulation with IL-2 of canine 
osteosarcoma cell lines produced a small increase in B7 expression in 3 of the 5 cell lines (60 
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% ) as indicated by an almost two-fold increase in the MFI of the cell lines stimulated with 
IL-2 compared to the without IL-2 stimulated cell lines. The remaining two cell lines ( 40 % ) 
did not show any appreciable increase in B7 expression, with their :MFI staying close to the 
baseline level, or a ratio approaching unity (Figure 5). 
Relation of ICAM-1 with different clinical parameters 
Where data was available, all five primary cell lines of dogs with osteosarcoma had 
high expression ofICAM-1 with 4 (80%) having sAP levels within normal range and one 
above the normal range. In frozen tissues of six dogs with osteosarcoma, 3 (50%) dogs had 
high expression ofICAM-1 and an sAP level within normal range, one dog had moderate 
ICAM-1 expression and an sAP within normal range, and two dogs with sAP level above the 
normal range with one moderate and one high ICAM-1 expression. In formalin-fixed, 
paraffin-embedded tissues of 11 dogs with osteosarcoma, 5 (45%) dogs had high expression 
ofICAM-1 and sAP levels within normal range, 4 (36%) dogs had moderate ICAM-1 
expression and sAP levels within normal range, and 4 dogs with sAP levels above normal 
range with one (9%) moderate and 3 (27%) high ICAM-1 expression. 
On the relation ofICAM-1 expression and metastasis, where data was present, 
primary cell lines of 3 of 4 (75%) dogs with metastasis had high ICAM-1 expression. On the 
other hand, high ICAM-1 expression was also observed in the primary cell line of one dog 
without metastasis. In frozen tissues of dogs with metastasis, 3 of 4 (75%) dogs exhibited 
high expression ofICAM-1. While one dog without metastasis showed high ICAM-1 
expression. The formalin-fixed, paraffin-embedded tissues of dogs with metastasis showed 
moderate (1 of 4, 25%) to high (2 of 4, 50%) ICAM-1 expression. However, one dog without 
metastasis high expression of ICAM-1 was observed. 
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Discussion 
Exploiting the immune system as a main modality for treatment of canine 
osteosarcoma is a major long-term goal of veterinary immunologists and clinicians. In the 
center of this approach is a need for a comprehensive understanding on how canine 
osteosarcoma cells relate to the major players of antitumor immunity, the CTL and NK cells, 
in terms of their expression of surface receptors critical to obtaining an optimum immune 
response. 
This study provides information on the expression ofICAM-1, :M:HC-1 and B7 
molecules in canine primary appendicular osteosarcoma cells and the possible implication of 
their expression in relation to tumor escape from immune effector cells. We have analyzed 
cell lines and tissue sections (frozen tissues and paraffin-embedded, formalin-fixed tissues) 
of dogs diagnosed with osteosarcoma by using fluorescence microscopy, flow cytometry and 
immunohistochemistry. 
ICAM-1 is crucial in initiating an antitumor immune response. At the same time, 
tumor progression has also been linked to ICAM-1 expression. This study showed that using 
immunoflourescence microscopic analysis, all five canine OSA cell lines demonstrated high 
surface expression for ICAM-1. Immunohistochemical analysis of frozen tumor sections 
showed a high percentage of staining for ICAM-1 in 4 of 7 ( 57 .1 % ) tumors from 7 dogs and 
only moderate staining in 3 of7 (43%) tumors from 7 dogs. In addition, one frozen tumor 
showed a weak expression. Almost the same pattern of staining was seen in formalin-fixed, 
paraffin-embedded tumor sections as in frozen tissues. ICAM-1 showed high staining 
expression for 10 of 17 (59%) tumors and moderate staining expression for 7 of 17 (41.2%) 
tumors. Taken together all three techniques correlated well for high ICAM-1 receptor 
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expression. Some evidence is suggested by the data that there are more dogs with 
osteosarcoma having metastasis and high ICAM-1 expression as observed in primary cell 
lines, frozen tissues, and formalin-fixed, paraffin-embedded tissues. However, a few cases 
were observed of dogs without metastasis which had high ICAM-1 expression. 
ICAM-1 present on these tumor cells should enable the adhesion and costimulation of 
immune effector cells optimizing their response to eliminate them. We sought to understand 
why canine OSA cells had escaped immune surveillance and what accounts for their rapid 
metastases/micrometastasis especially to the lungs and other sites. One hypothesis we tested 
was that they lacked adequate cell surface-adhesion molecules, rendering them unable to 
form stable conjugates with CTL or NK cells. Data from cell lines, frozen and paraffin-
embedded tissues show that canine osteosarcoma almost uniformly express constitutively 
high levels ofICAM-1. For canine osteosarcoma cells to survive, expressing ICAM-1 seems 
to be counterproductive as increased ICAM-1 expression should lead to increased attack by 
cytotoxic T cells and natural killer cells. On the other hand, ICAM-1 expression on tumor 
cells has been shown to correlate with a higher risk of the tumor cells to metastasize 
(Johnson, 1989; Simmons et al., 1995; Jiang et al., 1998; Sun et al., 1999). 
To metastasize, tumor cells must shed into the blood stream (intravasation) directly 
by invasion into the tumor-derived vasculature or indirectly by lymphatic drainage, survive 
in the circulation, and finally migrate through normal vascular endothelium and proliferate in 
the target organs ( extravasation). Tumor cell extravasation plays a key role in tumor 
metastasis. Several hypotheses have been proposed to explain tumor cell extravasation (El 
Sabban and Pauli, 1994; Kebers, 1998). However the precise mechanism by which tumor 
cells migrate through normal vascular endothelium remains controversial. It has been 
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proposed that increased ICAM-1 expression by tumor cells allows leukocytes to attach to 
them, and thus the tumor cells can "hitch a ride" on the leukocytes as they adhere to vascular 
endothelium and diapedese, enhancing the potential for hematogenous metastasis (Johnson, 
1991). 
Although, human polymorphonuclear neutrophils (PMNs), which comprise 50-70% 
of circulating leukocytes, can be spontaneously cytotoxic to tumor cells, they may function to 
promote tumor growth and metastasis as they might assist tumor cell extravasation during 
metastasis by transendothelial migration. A mechanism for this process was tested by Wu et 
al (200 I). By using an in vitro transendothelial migration model, they have demonstrated that 
tumor conditioned media-treated PMN assisted the migration ofMDA-:MB-231, a human 
breast tumor cell line, across an endothelial barrier. The transendothelial migration is due to 
the high levels ofICAM-1 expressed by this tumor and the upregulation of PMN CDI lb and 
CD 18 by the tumor culture media. It will be interesting to test if the canine osteosarcoma 
cells use a similar mechanism. This would have important clinical implications, particularly 
in the perioperative period when tumor cells are known to be present in the circulation and a 
transient leukocytosis occurs (Wu, 200 I). It is also important then to consider which 
immunotherapy protocol (i.e., cytokine treatment) to use in the treatment of this tumor. For 
example, granulocyte-macrophage colony-stimulating factor (GM-CSF) which stimulates 
production and recruits macrophages and granulocytes to the tumor area can in fact be used 
by the tumor cells for a "free ride to a greener pasture". 
It has been known for some time that malignant transformation of cells is frequently 
associated with altered MHC class I expression and/or function (Tanaka et al., 1988; Algarra 
et al., 1997; Hicklin et al., 1999.). Our analysis demonstrates that three of the five canine 
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osteosarcoma cell lines showed moderate expression ofMHC-1 expression while low 
expression was observed in two cell lines. In frozen tumor sections, MHC-1 staining 
demonstrated moderate expression in 4 of7 (57%) dogs while low staining occurred in 
tumors from 3 of7 (43%) dogs. In formalin-fixed, paraffin-embedded tumor sections, MHC-
1 showed moderate expression in tumors from 2 of 17 (8. 5%) dogs, low expression for 
tumors from 5 of 17 (29 %) dogs and negative staining in tumors from 10 of 17 (59 %) dogs. 
We attributed the difference in results between frozen and formalin-fixed tissues to 
inefficient antigen exposure. However, we could not directly test this hypothesis by 
comparing results from cell lines, frozen and formalin-fixed, paraffin-embedded tissues of 
the same animal due to the lack of clinical materials. 
The expression of negative to only moderate expression for MHC-1 can provide 
tumor cells with avenues for escape from immune recognition due to their role in presenting 
immunogenic peptides to T cells. However, complete lack of MHC-1 expression can expose 
tumor variants to NK cell attack, since they can lyse MHC class I-deficient targets. The 
present study demonstrates the presence of:MHC-1, albeit at low levels, and suggests that 
canine osteosarcoma may be able to stimulate immune effector cells but not efficiently. 
Altered expression of:MHC-1, whether complete loss or partial loss, can result from 
the selective pressure of tumor cells, which avoid recognition both by specific CTLs, and NK 
cells (Marincola et al., 2000). Different altered phenotypes seem to occur at the stage when 
the tumor breaks through the basal membrane, invades the surrounding tissues, and starts to 
metastasize. It has been reported that invasive human tumors totally or partially lose HLA 
antigens at a very high frequency-between 40% and 90% (Algarra et al., 1997). To put it 
succinctly, MHC-1 loss is advantageous to tumor growth and survival because it allows 
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escape from specific MHC-restricted CTLs, it then follows that the minimum loss that 
permits CTL evasion without consequently inducing NK-cell susceptibility will be selected 
for tumor survival. This scenario might be occuring with canine osteosarcoma cells since 
they cannot be contained by immune effector cells and persist to invade and spread to distant 
sites particularly to the lungs. While it is possible in human tumors to differentially identify 
which MHC class 1 altered phenotype is expressed by an individual tumor, it is not yet 
feasible in canine tumors (Hinklin et al., 1999). Knowledge of MHC-1 based escape 
mechanisms in tumors is relevant in terms of designing and implementing clinical 
immunotherapeutic protocols. As in patients that display constitutive loss of:MI-IC class 1 
expression, it might be appropriate to transfer functional, active MHC class genes. In 
addition, decreased expression ofHLA A, B, or C genes (locus-specific loss) can be partially 
restored by cytokines such as IFN-y in responsive tumors. Alternatively, in tumors that have 
completely lost expression of:MI-IC class 1 molecules, an appropriate therapy is to enrich for 
a particular NK- cell subset by IL-2 treatment that could attack the tumor cells. It is possible 
that some success in using IL-2 in cancer patients may be correlated with a previous loss of 
:MI-IC class 1 molecules by the tumor (Rees et al., 1999; Coulie et al., 1999). 
To determine whether the failure to obtain an optimum immune response could be 
due to lack of costimulatory molecules, B7 expression in canine osteosarcoma cell lines was 
analyzed. Flow cytometry analysis showed that 800/4 of the cell lines from 5 dogs expressed 
positive staining. Flow cytometry was used to measure B 7 in canine osteosarcoma cells 
because of the existing constraints on finding specific mAb against canine B7. Since we were 
expecting low-density cell surface expression ofB7 on canine osteosarcoma cells flow 
cytometry analysis was used. Flow cytometry has the advantage of detecting expression of 
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antigen at a lower protein concentration. To date, little is known about the expression ofB7 
molecules in dogs. The significance ofB7 expression in canine osteosarcoma is that these 
cells are able to provide costimulation to both T cells and NK cells (Chen et al., 1992; Luque 
et al., 2000). If they are then able to render costimulatory signals, how do we explain the 
failure of the canine osteosarcoma cells to stimulate optimum immune effector cells response 
that would lead to their elimination? Unlike APC where B7 molecules are abundantly found, 
it has been shown that most tumor cells, particularly the nonhematopoeitic origin (Chen et 
al., 1994) do not naturally express these molecules. Immunogenicity of the tumors is critical 
to the effect ofB7 costimulation on tumor immunity. When some nonimmunogenic tumors 
were transfected with B7, they continued to grow progressively (Chen et al., 1994). It was 
found that these nonimmunogenic tumors either lack molecules that can serve as tumor 
antigens or have deficient WIC class 1. The findings from our study show that although B7 
is expressed on canine osteosarcoma cells, it is associated with a low WIC-1 expression; that 
appears to be inadequate to achieve the optimum antitumor immunity against these tumors. 
However, since a high density ofB7 molecules is needed to trigger a full T cell response it 
could be that even with 80% of the cell lines showing high proportion of positive staining, 
the low MFI measured from canine osteosarcoma cells could mean a low density ofB7 that 
is insufficient to induce a T cell response. B7 molecules have been reported to be expressed 
by some progressive tumors (Koyama et al., 1998; Hersey et al., 1994). Reports show that 
some tumors, which express B7 molecules, even at low levels, preferentially bind to CTLA-4 
on T cells (Thompson and Allison 1997). Since CTLA-4 negatively regulates T cell 
activation this could explain their evasiveness from antitumor immunity. Since we detected 
B7 by using hCTLA-4Ig/Fc staining, we cannot differentiate at this time which B7 molecule 
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is expressed by canine appendicular osteosarcoma, B7-l, B7-2, or both, or whether the B7 
has a higher affinity for CTLA-4 than CD28. 
Because of the very promising use ofIL-2 for therapy against canine osteosarcoma 
(Khanna et al., 1997; Nieves, unpublished results), we examined the effect of exogenous IL-2 
in the expression ofICAM-1, :MHC-1 and B7 surface molecules. We demonstrated that IL-2 
did not have any effect in the expression ofICAM-1 and :MHC-1 on canine osteosarcoma 
cells. A similar finding was reported in human melanoma cell lines incubated with IL-2 for 
up to 72 hours wherein IL-2 did not modulate ICAM-1 expresssion on the cells (Altomonte 
M, 1993). In contrast, exogenous IL-2 downregulated expression of the HLA- class 1 
molecules and ICAM-1 on human carcinoma cell lines (Yasumura et al., 1994). However in 
a phenotypic analysis between parental and IL-2 gene transduced human squamous cell 
carcinoma of the head and neck cells there were no differences in expression ofHLA-class 1 
and ICAM-1 molecules (Nagashima et al., 1997). Human melanoma cells have been shown 
to express B7 molecules and increased expression is seen when these human melanoma cells 
are stimulated with IL-2 for 24-48 hours (Hersey et al., 1994). A marginal increase in B7 
expression is detected in 3 of 5 canine cell lines tested after treatment with IL-2. Thus, our 
results suggest that when used as a treatment modality to canine osteosarcoma, IL-2 will 
basically function in recruitment of immune effector cells, expansion of these cells, and an 
enhancement of their cytotoxic activity but can not regulate the expression ofICAM-1, 
:MHC-1 and B7 molecules on tumor cells. 
The data that there were more dogs with osteosarcoma having metastasis and high 
ICAM-1 expression as observed in primary cell lines, frozen tissues, and formalin-fixed, 
paraffin-embedded tissues. However, a few cases were observed_ of dogs without metastasis 
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with high ICAM-1 expression. High levels of alkaline phosphatase occur in normal fully 
differentiated mature osteoblast cells (Rodan and Rodan, 1984). Similar high levels were 
observed in osteosarcoma cells (Murray et al., 1987). Several clinical studies demonstrated 
that high serum alkaline phosphatase is an important prognostic factor for appendicular 
osteosarcoma in dog and human osteosarcoma (Ehrhart et al., 1998; Bacci et al., 1993). Dogs 
from this study demonstrated variable serum alkaline phosphatase concentration. In addition 
they showed no definitive relationship between serum alkaline phosphatase level and the 
existence of metastasis. 
In summary, the results of the study demonstrate a high level ofICAM-1 expression 
in canine primary osteosarcoma, which could possibly explain the invasive nature and rapid 
metastasis of this malignant tumor. B7 expression suggests that these tumors are able to 
deliver a costimulatory signal but manage to escape from immune effector cells, perhaps due 
to low :MHC-1 expression. These results are consistent with the theory that the tumor cells 
could decrease MHC-1 expression to interfere with antigen presentation while possibly 
maintaining sufficient :MHC-1 expression to deliver an inhibitory signal to NK cells. 
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CHAPTER 3. GENERAL DISCUSSION AND CONCLUSION 
The advantage of using clinical tumor cases (spontaneously occurring tumors) for 
studying the immunobiology of canine osteosarcoma was discussed by Vail and McEwen 
(2000) in their recent paper. They observed that most investigators have used inbred rodent 
models and laboratory derived canine populations to gather data for their study on canine 
tumors. Working with inbred rodent populations in artificial environments brings some 
degree of concern over the applicability of information gathered as it relates to naturally 
occurring tumors in dogs or people. They claim that to dispel most concerns, study of 
spontaneously occuring tumors in companion animals such as dogs and cats is highly 
recommended. These animals share a common environment with people and therefore 
exposure to environmental contributors to carcinogenesis should be similar. Malignancies in 
companion animals develop spontaneously, whereas many experimental models use induced 
tumors either through exposure to known carcinogens or transplantation, often in the 
presence of artificially induced immunologic modification. 
For the purposes of this study, we analyzed canine osteosarcoma cell lines from 
spontaneously occurring primary appendicular osteosarcoma previously reported and some 
developed during the course of this work. The immunobiological behavior of canine 
osteosarcoma is most readily studied when the cells are growing in culture. Established 
tumor cell lines reflect the differentiated features of tissue origin with cellular immortality, 
characteristics that make them an ideal in vitro system for tumor studies. To minimize 
occurrences of intra-tumor variability, analysis was done on early cell cultures passages. 
Early cell cultures passages are suitable templates for immunotherapy vaccines. 
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On the other hand, it is possible that in vitro establishment of canine osteosarcoma cell lines 
selects a population of tumor cells with altered surface expression ofICAM-land MHC-1. 
Thus, it was important to determine whether similar expression could also be demonstrated in 
tissues. 
Since antigen is better preserved and detected in frozen state, tumor biopsies 
preserved as frozen tissue sections were stained for immuno- histochemistry. Important to all 
histological and cytological techniques is the preservation of cells and tissues in as close to 
life-like a manner as possible. This is accomplished by fixing them with commonly used 
formalin, which is superior for morphologic preservation but leads to antigen loss (Shi et al., 
1991). A persistent goal in immunopathology then is to develop ways to provide maximal 
preservation of tissue morphology with minimal loss of antigenicity. With existing archives 
of formalin-fixed, paraffin-embedded tumor tissue sections of canine osteosarcoma cases 
available, we expanded the study in this tissue type preparation. And to solve the dilemma of 
possible masking of antigens due to fixation, several antigen retrieval techniques were used 
on the tumor tissues before proceeding to immunohistochemistry analysis. 
Additionally, the present study provides new insights on how to approach 
immunotherapeutic strategies for canine appendicular osteosarcoma particularly on its 
characteristic rapid pulmonary metastasis. Considering high level ofICAM-1 expression, the 
beneficial effects oftransducing tumor cells with GM-CSF, a pro-Inflammatory cytokine can 
only contribute to the availability of more leukocytes where the tumor cells can adhere and 
"hitch-a-ride" to metastasize to other sites, especially to the lungs. Expression of:MHC class 
I is an important criterion when considering T-cell based imunotherapy. Therefore, selecting 
patients for clinical trials based on their ability to express normal levels ofMHC class I is 
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highly recommended. Since our findings show low expression of MHC class I in the canine 
osteosarcoma cases we tested, a question of what type of loss or downregulation has occurred 
must be considered. This area in canine patients is not well studied yet due to the constraints 
imposed by unavailability of reagents and specific monoclonal antibodies to canine MHC-1. 
One study of canine mammary tumors and melanoma demonstrated that MHC class I 
expression in these tumors could be increased by canine IFNy treatment (Whitley et al., 
1995). 
Taken together, our data provide information in the expression ofICAM-1, MHC-1 
and B7 molecules on canine appendicular osteosarcoma. These surface molecules are very 
crucial in determining an optimum immune response of effector cells such as T and NK cells 
against tumor cells. The results also clarify certain aspects of canine appendicular 
osteosarcoma immunobiology. The presence ofICAM-1 denotes that these tumor cells can 
adhere and form stable interactions with immune effector cells. This can additionally 
contribute to costimulation of immune effector cells. Despite this functional significance it is 
difficult to dismiss the significance of the widespread high level of expression of ICAM-1 on 
these malignant cells. Based on the highly invasive and rapid metastases of canine 
osteosarcoma particularly to the lungs, the seeming ability to escape immune surveillance 
and reports from other tumor studies, we strongly suggest that these cells use ICAM-1 
instead to promote their growth and metastasis. The low expression of MHC class 1 on 
canine appendicular osteosarcoma might render them resistant to effector T cells. In contrast, 
low expression ofMHC class I on these tumors makes them susceptible to NK cells 
according to 'missing self hypothesis'. While this expectation might hold true the possibility 
still exist that canine osteosarcoma by selective pressures might generate tumor variants with 
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minimum MHC class 1 loss that pennits CTL evasion and at the same time retaining MHC 
class 1 proteins that inhibit NK activity (via KIRs). Immune recognition is aided in that B7 
expression is detected in canine osteosarcoma meaning that they can deliver costimulation 
when needed. Although to what extent is costimulation occurring is questionable because the 
low mean fluorescence intensity could reflect low density ofB7, which might not be enough 
to induce sufficient T cell response. Alternatively, B7 could bind preferentially to CTLA-4, 
the negative regulator ofT cells in which B7 molecules have higher affinity (Thompson and 
Allison, 1997). We believe the baseline information we gathered on these surface receptors 
will contribute to a better understanding of canine osteosarcoma. 
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